Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB) -- Ignore unavailable to you. Want to Upgrade?

To: alex s. who wrote (753)	12/15/1999 3:05:00 PM
From: Dauntless	Read Replies (1) \| Respond to of 834

Alex - Plenty pending 1- The re-submission of their first drug is due for an FDA decision by 2/16/00. 2- They have been in negotiations for a partner for their second compound for quite some time & a deal is expected soon. 3- They are nearly completed with a plan to form a company in Germany in order to take advantage of German Gov't. incentives to attract high tech industry. This newco would take the third drug (for asthma) thru phases I & II of clinical trials. Newco would have distrib. rights for Germany. TXB will own ~51% of Newco - voila, drug development financed off balance sheet. None of this is certain but time is drawing short for #1. Maybe some leaks somewhere - no official news from TXB. Hope you were in for a while.